MedTrace Logo

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

NCT00051545 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 608

Last updated 2025-02-25

No results posted yet for this study

Summary

To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC).

Conditions

  • Liver Neoplasms

Interventions

DRUG

Seocalcitol

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Hanne Hvidberg, MScPharm PhD · LEO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Completion
2004-06-30

Countries

  • Canada
  • France
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051545 on ClinicalTrials.gov